Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Waters Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $41.7B | |
|---|---|---|
| Revenue (ttm) | 4.6B | |
| Net income (ttm) | 166.6M | |
| EPS (ttm) | $2.21 | |
| Shares out | 98.2M | |
| P/E (trailing) | 215.3x | |
| P/E (forward) | 24.8x | |
| Volume | 722,879 | |
| Beta | 1.15 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.79B | $2.97B | $2.96B | $2.96B | $3.17B | +3.2% |
| Gross profit | $1.63B | $1.72B | $1.76B | $1.76B | $1.83B | +2.9% |
| Operating income | $821.7M | $873.4M | $817.7M | $826.4M | $802.6M | -0.6% |
| Net income | $692.8M | $707.8M | $642.2M | $637.8M | $642.6M | -1.9% |
| EPS (diluted) | $11.17 | $11.73 | $10.84 | $10.71 | $10.76 | -0.9% |
| EBITDA | $982.8M | $1.02B | $817.7M | $1.04B | $1.01B | +0.7% |
| R&D | $168.4M | $176.2M | $174.9M | $183.0M | $195.7M | +3.8% |
| SG&A | $627.0M | $658.0M | $736.0M | $690.1M | $830.4M | +7.3% |
Recent company headlines from major financial publishers.
Under the modal base path, Waters delivers steady compound growth anchored by recurring chemistry consumables ($631.46M in FY2025) and service revenues ($1,188.19M). Top-line revenue expands from $6,466.84M in FY2026 to $7,136.40M in FY2027, while operating margins improve gradually toward long-term targets by FY2030 supported by 90 bps of pricing realization. Disciplined capital allocation and share buybacks offsetting SBC support diluted EPS progression from $14.58 in FY2026 to $16.54 in FY2027, yielding a synthesized fair value midpoint of $345.34.
Under the upside trajectory, biopharmaceutical R&D and lab capital expenditure rebound sharply across North America and Europe, accelerating replacement across the 12,000-unit installed base. Expanding GLP-1 testing volumes and reagent rental compliance across 700 accounts lift pricing realization to 150 bps, while biopharma reshoring drives incremental lab placements through 2030. Operating margins expand toward 28-30%, supporting compound diluted EPS growth above consensus expectations toward the upper fair value boundary ($440.18).
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.6% | $340 | $346 | $352 | $359 | $367 |
| 9.1% | $324 | $329 | $334 | $339 | $346 |
| 9.6% | $310 | $314 | $345 | $323 | $328 |
| 10.1% | $298 | $301 | $304 | $308 | $313 |
| 10.6% | $287 | $289 | $293 | $296 | $299 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
